Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis

B. M. Solomon, K. G. Chaffee, J. Moreira, S. M. Schwager, J. R. Cerhan, T. G. Call, N. E. Kay, S. L. Slager, T. D. Shanafelt*

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

It is unknown whether individuals with monoclonal B-cell lymphocytosis (MBL) are at risk for adverse outcomes associated with chronic lymphocytic leukemia (CLL), such as the risk of non-hematologic cancer. We identified all locally residing individuals diagnosed with high-count MBL at Mayo Clinic between 1999 and 2009 and compared their rates of non-hematologic cancer with that of patients with CLL and two control cohorts: general medicine patients and patients who underwent clinical evaluation with flow cytometry but who had no hematologic malignancy. After excluding individuals with prior cancers, there were 107 high-count MBL cases, 132 CLL cases, 589 clinic controls and 482 flow cytometry controls. With 4.6 years median follow-up, 14 (13%) individuals with high-count MBL, 21 (4%) clinic controls (comparison MBL P<0.0001), 18 (4%) flow controls (comparison MBL P=0.0001) and 16 (12%) CLL patients (comparison MBL P=0.82) developed non-hematologic cancer. On multivariable Cox regression analysis, individuals with high-count MBL had higher risk of non-hematologic cancer compared with flow controls (hazard ratio (HR)=2.36; P=0.04) and borderline higher risk compared with clinic controls (HR=2.00; P=0.07). Patients with high-count MBL appear to be at increased risk for non-hematologic cancer, further reinforcing that high-count MBL has a distinct clinical phenotype despite low risk of progression to CLL.

Original languageEnglish (US)
Pages (from-to)331-336
Number of pages6
JournalLeukemia
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis'. Together they form a unique fingerprint.

  • Cite this

    Solomon, B. M., Chaffee, K. G., Moreira, J., Schwager, S. M., Cerhan, J. R., Call, T. G., Kay, N. E., Slager, S. L., & Shanafelt, T. D. (2016). Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia, 30(2), 331-336. https://doi.org/10.1038/leu.2015.235